Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data

The approach that J&J has been taking to precision medicine for neuropsychiatry received some validation Wednesday with the pharma’s announcement that its OX2R-targeting therapy seltorexant met the primary and secondary endpoints in a Phase III trial to treat patients with major depressive disorder (MDD) experiencing insomnia.

Although Johnson & Johnson (NYSE:JNJ) did not disclose the data, it said adjunctive treatment with seltorexant led to a statistically significant improvement in depressive symptoms based on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at day 43, and improved sleep outcomes in patients inadequately controlled on SSRI/SNRI antidepressants alone. J&J will present the findings at the American Society of Clinical Psychopharmacology, which runs May 28-31...